Network pharmacology analysis reveals potential targets and mechanisms of proton pump inhibitors in breast cancer with diabetes
Network pharmacology analysis reveals potential targets and mechanisms of proton pump inhibitors in breast cancer with diabetes
复制标题
DOI：
10.1038/s41598-023-34524-x
复制
发表时间：
2023
影响因子：
4.6
通讯作者：
Taolan Zhang
中科院分区：
文献类型：
--
作者：
Haihong Hu;Hanbin Wang;Xiaoyan Yang;Zhicheng Li;Wendi Zhan;HongXia Zhu;Taolan Zhang
Breast cancer and diabetes are signifcant health challenges, and efective treatments for both .diseases are lacking. Proton pump inhibitors (PPIs) have demonstrated anticancer and hypoglycemic .efects, but their mechanisms of action are not yet fully understood. We used the GeneCards and .PharmMapper databases to identify therapeutic targets for diabetes, breast cancer and PPIs. We .identifed common targets and constructed a regulatory network of diseases and drugs using the .STRING database and Cytoscape software. We also explored the binding between small molecule .ligands and protein receptors using Discovery Studio software. We identifed 33 shared targets for .breast cancer, diabetes, and PPIs including lansoprazole, omeprazole, and pantoprazole, which .play a critical role in fatty acid transport, insulin resistance, apoptosis, and cancer-related signaling .pathways. Our fndings demonstrated that PPIs had a strong afnity for AKT1 and MMP9. This study .provides insights into the mechanisms of action of PPIs in breast cancer and diabetes and identifes .AKT1 and MMP9 as critical targets for future drug development. Our fndings highlight the potential of .PPIs as a novel therapeutic approach for these challenging diseases.
